亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

氯唑沙宗

 
 
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
過期 長期有效
更新 2011-04-16 11:44
 

武漢遠城科技發展有限公司銷售八部

企業會員第16年
資料未認證
保證金未繳納
詳細說明
氯唑沙宗 
英文名稱: Chlorzoxazone 
別名:氯苯惡唑酮; 氯羥苯惡唑; 氯羥苯噁唑;氯唑沙噻
化學名:5-氯-2-苯并噁唑啉酮 
CAS號: 95-25-0 
分子式: C7H4ClNO2 
分子量: 169.57 
EINECS號: 202-403-9 
外觀:白色結晶或結晶性粉末,無臭,無味。
熔點:191-193℃
氯含量:20.6-21.2%
含量:98-102% 
質量標準:CP2005/USP29
包裝:25公斤/桶
用途:中樞性肌肉松弛劑,解熱鎮痛類藥,用于治療急性骨骼肌扭傷,關節、軟組織扭傷。 
儲藏:避光,密封保存。
Chlorzoxazone
Alias: chlorobenzene oxazolone; chloro phenyl hydroxy oxazole;
 chloro benzene hydroxy oxazole; chloride yl thiophene sand
Chemical Name: 5 - chloro -2-- benzoxazole Morpholinone
CAS Number: 95-25-0
Molecular formula: C7H4ClNO2
MW: 169.57
Packing: 25kg cardboard drum
EINECS Number: 202-403-9
Appearance: white crystal or crystalline powder, odorless, tasteless.
Melting point :191-193 ℃
Chlorine content :20.6-21.2%
Content :98-102%
Quality Standard: CP2005/USP29
Packaging: 25 kg / barrel
Uses: central muscle relaxants, anti-inflammatory drugs, for 
the treatment of acute muscle sprains, joint and soft tissue sprain.
Storage: protected from light, sealed.
舉報收藏 0評論 0
更多>本企業其它產品
羅非昔布 美羅培南 美洛昔康 美索巴莫 尼美舒利 帕馬溴 潑尼松龍
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |